The company has explored FDA Emergency Use Authorisation potential with their regulatory consultants, but it sounds like they are not going to pursue this short term approval aggressively. The next step is waiting for a meeting to determine next steps.
Yesterdays announcement will help with clinical validation and cost benefit analysis, but another indefinite free licensing deal for me isn't the right strategy for the company. Particularly considering the German trial which originally aimed to achieve this is now on pause.
I continue to wonder why ResApp haven't secured licensing deals or freemium arrangements with their testing hospitals in Australia. These hospitals already understand best use cases and workflow for the technology.
Tony mentioned the company needs to be efficient onboarding Telehealth clients, it's obvious the current deals are taking far too long to come online. The company is unable to forecast revenue guidance.
